As of November 6, 2026, Tarsus Pharmaceuticals, Inc. is a publicly traded company (Nasdaq: TARS); its largest reported holder is Deep Track Capital, with 8.46% on Schedule 13G/A of May 15, 2026, then RTW Investments (8.1%). The largest insider holding is Bobak R. Azamian, the chairman and chief executive, with 861,412 shares (1.7% of shares outstanding), per Form 4 of September 9, 2026 (Schedule 13G/A, May 15, 2026).
Is this your company?
About to sign with, pay or invest in Tarsus Pharmaceuticals, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Tarsus Pharmaceuticals, Inc. a real, registered company?
- Tarsus Pharmaceuticals, Inc. files with the SEC under CIK 1819790 (its SEC filings).
- Its shares are listed under the ticker TARS on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Irvine, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under TARSUS PHARMACEUTICALS INC in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Fidelity (FMR) (filed 2026-11-05).
Who are Tarsus Pharmaceuticals, Inc.'s owners and officers?
Tarsus Pharmaceuticals, Inc.: incorporated in Delaware; business address in Irvine, California; industry Biological Products, (No Diagnostic Substances) (Schedule 13G, 2026-11-05).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-11-05 | Fmr LLC | 6.4% |
| Schedule 13G/A, 2026-08-13 | Janus Henderson Group LTD. | 6.5% |
| Schedule 13G, 2026-05-15 | Janus Henderson Group PLC | 5.3% |
| Schedule 13G/A, 2026-05-15 | Deep Track Capital, LP | 8.46% |
| Schedule 13G/A, 2026-05-08 | Prudential Financial Inc | 4.3% |
| Schedule 13G/A, 2026-05-06 | Jennison Associates LLC | 4% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-17 | Tang Capital Management, LLC | 2.8% |
| Schedule 13G/A, 2025-11-14 | Deep Track Capital, LP | 7.11% |
| Schedule 13G/A, 2025-08-14 | Rtw Investments, LP | 8.1% |
| Schedule 13G, 2025-07-28 | Deep Track Capital, LP | 5.6% |
Questions about who owns Tarsus Pharmaceuticals, Inc.
Who owns Tarsus Pharmaceuticals, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Tarsus Pharmaceuticals, Inc.: Deep Track Capital, LP (8.46%, Schedule 13G/A, filed 2026-05-15), Rtw Investments, LP (8.1%, Schedule 13G/A, filed 2025-08-14), Janus Henderson Group LTD. (6.5%, Schedule 13G/A, filed 2026-08-13), Fmr LLC (6.4%, Schedule 13G, filed 2026-11-05) and Janus Henderson Group PLC (5.3%, Schedule 13G, filed 2026-05-15).
Who are the largest shareholders of Tarsus Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of Tarsus Pharmaceuticals, Inc. on this page are Deep Track Capital, LP (8.46%), Rtw Investments, LP (8.1%) and Janus Henderson Group LTD. (6.5%).
When did Deep Track Capital, LP buy into Tarsus Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Deep Track Capital, LP on this page is the Schedule 13G, filed 2025-07-28, reporting 5.6%; its latest, Schedule 13G/A filed 2026-05-15, reports 8.46%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 11 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Tarsus Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Tarsus Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Tarsus Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Tarsus Pharmaceuticals, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chairman and chief executive: 861,412 shares (1.7% of shares outstanding), 33,421 held directly and 827,991 indirectly (Form 4, 2026-09-09).
- , a director: 94,487 shares (0.19% of shares outstanding) (Form 4, 2026-09-17).
- , the chief operating officer: 79,007 shares (0.16% of shares outstanding), 78,532 held directly and 475 indirectly (Form 4, 2026-09-09).
- , the general counsel: 63,959 shares (0.13% of shares outstanding) (Form 4, 2026-03-19).
- , the chief commercial officer: 61,480 shares (0.12% of shares outstanding) (Form 4, 2026-03-19).
Shares outstanding: 49,305,552 as of 2026-10-29, from the company's latest SEC cover page.
How much has Tarsus Pharmaceuticals, Inc. raised?
Acquisitions reported on Form 8-K, Item 2.01: acquired Alkeus Pharmaceuticals, Inc. (2026-09-10).
Keep reading
More on Tarsus Pharmaceuticals, Inc. and the records around it.
Tarsus Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Acquisition Sep 2026
Companies that share a holder
- Jennison Associates LLC also filed stake reports on 14 other companies: LENDINGTREE INC (Oct 2026), PALVELLA THERAPEUTICS INC (Oct 2026), REZOLUTE INC (Oct 2026)
- PRUDENTIAL FINANCIAL INC also filed stake reports on 20 other companies: National Healthcare Properties, Inc. (Oct 2026), Neurogene Inc. (Oct 2026), PALVELLA THERAPEUTICS, INC. (Aug 2026)
- TANG CAPITAL MANAGEMENT, LLC also filed stake reports on 33 other companies: EyePoint, Inc. (Oct 2026), Skye Bioscience, Inc. (Oct 2026), Nano Dimension Ltd. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/tarsus-pharmaceuticals